NNF Center for Basic Metabolic Research

Common and distinct roles of AMPKγ isoforms in small-molecule activator-stimulated glucose uptake in mouse skeletal muscle Objective: Small-molecule activators targeting the allosteric drug and metabolite (ADaM) site of AMPK enhance insulin-independent glucose uptake in skeletal muscle and lower glucose in preclinical mod...

Check out our latest preprint from the lab, spearheaded by researcher @itsmedipsikha.bsky.social , investigating the distinctive roles of regulatory gamma subunits of the AMPK protein complex in small molecule activator-stimulated skeletal muscle glucose uptake.
www.biorxiv.org/content/10.1...

Great visit to Novo Nordisk Foundation Center for Genomic Mechanisms of Disease in Boston at Broad Institute. Delighted to see great collaborations with Novo Nordisk Foundation Center for Basic Metabolic Research @cbmr.science @novo-nordisk.bsky.social

😅

Remember to sign up for the Gut-Brain Axis @keystonesymposia.bsky.social meeting in March 2026!

Upcoming deadlines:
Scholarship Deadline: November 18, 2025
Short Talk Abstract Deadline: November 18, 2025

Organizers: Martin G. Myers, Jr., Darleen A. Sandoval and Tune H Pers

keysym.us/KSGutBrain26

Cold-season programming reinforces the brown fat–cardiometabolic health link Recent work by Yoneshiro et al. links brown adipose tissue (BAT) activity to environmental temperatures during conception, highlighting intergeneratio…

Read the Spotlight article in Nature Metabolism, here:

'Cold-season programming reinforces the brown fat–cardiometabolic health link'

www.sciencedirect.com/science/arti...

2/2

Could the season you were conceived determine your lifelong health?

@camillascheele.bsky.social & Taylah Gaynor ask why cold temperatures during the pre-conception period are associated with higher BAT density and activity and point to a possible epigenetic reprogramming of the father's sperm.

1/2

Graphic with a cyan and blue background introducing EFSD Recipient Research Portrait. A photo of Associate Professor Atul S. Deshmukh is shown inside a circular frame. Text reads: "Associate Professor Atul S. Deshmukh, Novo Nordisk Foundation Center for Basic Metabolic Research." EFSD logo with tagline "European Foundation for the Study of Diabetes" appears at the bottom.

Graphic with a green and blue background and the EFSD logo. Heading reads: "Discovery of insulin sensitizing peptides and proteins for the treatment of type 2 diabetes." Text explains Atul S. Deshmukh’s research: He aims to identify and validate exercise-induced, insulin-sensitizing peptides and proteins as therapeutics for type 2 diabetes. Using human, rodent, and cell models with advanced proteomics, he uncovers novel muscle-derived secreted factors (myokines) that mimic beneficial metabolic effects of exercise.

Graphic with a blue background and EFSD logo. Text reads: "Supported by the EFSD/Novo Nordisk Foundation Future Leaders Award." Below: "Apply for research grants and fellowships. europeandiabetesfoundation.org."

💡Meet Assoc. Prof. @adeshmukh.bsky.social ( @cbmr.science), #EFSD/ @novo-nordisk.bsky.social Future Leaders Awardee. His work uncovers exercise-induced peptides & #proteins that improve insulin sensitivity in #T2D.

📅 See him at #EASD2025 (18 Sept, 12:45 CEST, Milan Hall).

📖 doi.org/10.1016/j.ce...

Mechanism and cellular actions of the potent AMPK inhibitor BAY-3827 The mechanism and unique molecular/cellular features of the potent and selective AMPK inhibitor BAY-3827 are unraveled.

Latest publication from the lab spearheaded by @shoreseashell.bsky.social & in collaboration with @zeqiraj.bsky.social is out. Using structural, biochemical & computational tools, this work sheds light on the mechanism of action of BAY-3827 in inhibiting #AMPK 1/3
www.science.org/doi/full/10....

Are you using metabolic tolerance tests in your research? 💉Are you interested in metabolites? Or do you study the effects of exercise? 🏃🏻‍♂️‍➡️ 1/4

Congratulations to Niclas Rausch, Rebecca L. McIntyre, Fabian Finger & Jens Lund of cbmr.science for winning the #JournalClub 2024 Prize! 📖 🏆

See their winning paper 'Cutting through dogma: a novel tool to dissect lactate biology'⬇️

physoc.onlinelibrary.wiley.com/doi/10.1113/...

@jphysiol.bsky.social, and several other journals, has a 'Journal Club' format targeted to early-career researchers. It is a great opportunity for young scientists to get started with scientific writing and cultivating independent thinking. Check it out! 1/3

A must read!

@cellpress.bsky.social Review 🚨 ‘Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy’

Lead author: @johansenvbi.bsky.social
Senior author: @clemmensenc.bsky.social

Read it here: www.cell.com/cell/fulltex...

Looking for a Postdoc position? (great program with 3-year funding and running costs)

@clemmensenc.bsky.social has a fantastic project in wonderful Copenhagen at the fantastic @cbmr.science research center

Being a program alumni I can can highly recommend the program and the Clemmensen lab :)

Commentary by Researcher @itsmedipsikha.bsky.social on the emerging role of glycogen metabolism in regulating energy homeostasis in adipose tissue is out now on @natrevendo.nature.com @cbmr.science

www.nature.com/articles/s41...

After an immensely enriching and rewarding PhD in @caina89.bsky.social lab at @pioneercampus.bsky.social, I am excited to announce that I moved to beautiful Copenhagen for my postdoc in Simon Rasmussen's group @cbmr.science!

Kickstart your research career in Copenhagen with a PhD or Postdoctoral fellowship at CBMR!

Four PhD and four Postdoc positions are currently available:

cbmr.ku.dk/join-us/fell...

#phdposition #postdocposition

🔎 𝐃𝐞𝐜𝐢𝐩𝐡𝐞𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐆𝐈𝐏 𝐩𝐚𝐫𝐚𝐝𝐨𝐱

Why does activating the GIP receptor contribute to weight-loss, given the evidence that blocking the receptor ought to be more effective?

Prof. Jens Juul Holst outlines the evidence in Diabetes 👇

diabetesjournals.org/diabetes/art...

#GIP #GLP1 #biotech #obesity

Safety becomes more important than foraging when a specific neuronal circuit in the brain is activated Researchers from the University of Copenhagen have identified a neural circuit in the mouse’s brain which ensures that it prioritises safety over other needs, e.g. food seeking, and that this happens ...

Scientists from @cbmr.science and the @ucph.bsky.social Department of Neuroscience have identified a neural circuit in the mouse’s brain that prioritises safety over other needs. The findings were published in @nature.com Neuroscience.

Read more, below 👇

healthsciences.ku.dk/newsfaculty-...

Insulin- and exercise-induced phosphoproteomics of human skeletal muscle identify REPS1 as a regulator of muscle glucose uptake Skeletal muscle glucose uptake, essential for metabolic health, is regulated by both insulin and exercise. Using phosphoproteomics, we analyze skeleta…

Insulin- and exercise-induced phosphoproteomics of human skeletal muscle identify REPS1 as a regulator of muscle glucose uptake
Great collaboration with @adeshmukh.bsky.social @JeppeKjaergaard.bsky.social and team @cbmr.science

www.sciencedirect.com/science/arti...

Insulin- and exercise-induced phosphoproteomics of human skeletal muscle identify REPS1 as a regulator of muscle glucose uptake Skeletal muscle glucose uptake, essential for metabolic health, is regulated by both insulin and exercise. Using phosphoproteomics, we analyze skeleta…

New publication!

We mapped the phosphoproteomic landscape of insulin & exercise in human skeletal muscle (same individuals) and discovered REPS1 as a new regulator of muscle glucose uptake.

www.sciencedirect.com/science/arti...

@cbmr.science @jeppekjaergaard.bsky.social

Body Fluid Proteomic Landscape of Acute Exercise Physical activity improves health, yet the molecular mechanisms remain partially understood. This study presents a high-resolution, time-resolved atlas profiling 10,127 proteins across plasma, saliva,...

Preprint Alert
We present the most comprehensive, time-resolved atlas of the human proteomic response to acute exercise. We mapped 10,000+ proteins across plasma, saliva & urine—3,000+ changed after just one workout.
doi.org/10.1101/2025...
Explore cbmr-rmpp.shinyapps.io/exerome/

Special day for our group @cbmr.science as we celebrate the successful defense of our (first) freshly minted PhD, Dr. Conchita Bringas 🥳 Her thesis was based on characterizing novel #AMPK inhibitors. Special thanks to the great committee @rbdamgaard.bsky.social ,Dave Carling & Lykke Sylow.

Thrilled to share that our manuscript mapping proteomic & phosphoproteomic signatures of NGT, T2D, males & females — before and after hyperinsulinemic-euglycemic clamp — is now accepted in Cell.

@annakrook.bsky.social @juleenrzierath.bsky.social
@cbmr.science

doi.org/10.1016/j.ce...

Promotional graphic for the 61st EASD Annual Meeting, taking place from 15–19 September 2025 in Vienna, Austria. The background is red with a white Ferris wheel illustration on the right-hand side. At the top left, the EASD 2025 Vienna logo is displayed. Large blue text reads “61st EASD Annual Meeting” with event dates and location beneath. In the centre-left, a blue and white banner highlights the “Rising Star Award” recipient, Dr. Jens Lund. To the right, there’s a circular photo of Dr. Jens Lund, a man with short light brown hair, wearing a black and white striped shirt, smiling against a light grey background. At the bottom left is the EASD logo, and the website easd.org appears at the bottom right.

🏆 Congrats Dr. Jens Lund (@cbmr.science &
& @ucph.bsky.social) for being awarded the EASD Rising Star Symposium & #EFSD Rising Star Fellowship for his research project: Circulating metabolites regulating energy homeostasis.

Looking forward to your #EASD2025 lecture & wish you continued success👏

CBMR spinout Ousia Pharma has secured significant seed funding from the Boston-based venture fund Omega Funds to support the preclinical and clinical development of a once-weekly, dual-incretin-NMDA receptor antagonist conjugate.

cbmr.ku.dk/news/2025/cb...

@clemmensenc.bsky.social

#biotech #glp1

Excited to share another great collaborative effort — we successfully combined single muscle fiber proteomics with functional assays in the same fiber! This integrated approach allows a direct link between molecular composition and functional performance at the single cell/fiber level.

Precision nutrition for cardiometabolic diseases - Nature Medicine This Review critically examines the evidence base in precision nutrition research, discusses the challenges in translating short-term studies into long-term clinical effectiveness and highlights the m...

Closing the week with exciting news! Our latest work, a review on #PrecisionNutrition for cardiometabolic diseases, has been published in @naturemedicine.bsky.social 😄

www.nature.com/articles/s41...

Precision nutrition for cardiometabolic diseases - Nature Medicine This Review critically examines the evidence base in precision nutrition research, discusses the challenges in translating short-term studies into long-term clinical effectiveness and highlights the m...

🥗 🎯 @martaguasch1.bsky.social & @jmerino.bsky.social release a Review in @nature.com Medicine on precision nutrition for cardiometabolic disease, examining the evidence base, exploring the potential benefits, and discussing the challenges and opportunities ahead. 👇

www.nature.com/articles/s41...

Incretin-based therapeutics for the treatment of neurodegenerative diseases Neurodegenerative diseases (NDDs) represent a heterogeneous group of disorders characterized by progressive neuronal loss, which results in significant deficits in memory, cognition, motor skills, and sensory functions. As the prevalence of NDDs rises, there is an urgent unmet need for effective therapies. Current drug development approaches primarily target single pathological features of the disease, which could explain the limited efficacy observed in late-stage clinical trials. Originally developed for the treatment of obesity and diabetes, incretin-based therapies, particularly long-acting GLP-1 receptor (GLP-1R) agonists and GLP-1R–gastric inhibitory polypeptide receptor (GIPR) dual agonists, are emerging as promising treatments for NDDs. Despite limited conclusive preclinical evidence, their pleiotropic ability to reduce neuroinflammation, enhance neuronal energy metabolism and promote synaptic plasticity positions them as potential disease-modifying NDD interventions. In anticipation of results from larger clinical trials, continued advances in next-generation incretin mimetics offer the potential for improved brain access and enhanced neuroprotection, paving the way for incretin-based therapies as a future cornerstone in the management of NDDs. This Review summarizes preclinical and clinical evidence highlighting the potential of incretin-based drugs as treatments of neurodegenerative diseases, such as Alzheimer’s disease or Parkinson’s disease.

REVIEW | A Vear, MT Heneka and @clemmensenc.bsky.social
( @cbmr.science , @umasschan.bsky.social )

Review on the potential of incretion-based drugs as treatments of neurodegenerative diseases